FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO72 | CATHETER-RELATED THROMBOSIS VS. FIBROBLASTIC SLEEVE. INCIDENCE AND IMPACT IN ONCOLOGICAL AND HEMATOLOGICAL PATIENTS WITH PERIPHERALLY INSERTED CENTRAL CATHETER M. Nunziata1, S. Mangiacapra1, F.P. Damiano1, N. Iuliano1, V. Iorio1, R. Natale2, L. Santarpia2, M. Amitrano1 | 1Internal Medicine, A.O.R.N. San Giuseppe Moscati, Avellino, Italy; 2Internal Medicine, Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy
3PDF: 1 -
PO70 | HEMOSTATIC ABNORMALITIES IN A PATIENT WITH WALDENSTRÖM'S MACROGLOBULINEMIA M. Gagliardi, L. Capone, A. Ciampa | Haemostasis Centre, AORN Moscati, Avellino, Italy
1PDF: 0 -
PO69 | INCIDENTAL CANCER DETECTED DURING EMERGENCY DIAGNOSTIC WORK-UP FOR ACUTE PULMONARY EMBOLISM: A RETROSPECTIVE COHORT STUDY L. Mocerino1, A. Casoria2, S. Mangiacapra2, M. Amitrano2, V. Bassi3, A. Tufano1 | 1Department of Clinical Medicine and Surgery. Federico II University of Naples, Italy; 2Internal Medicine Unit, Moscati Hospital, Avellino, Italy; 3U.O.C. di Medicina Generale e Lungodegenza, San Giovanni Bosco Hospital, ASL; Na1 Centro, Naples, Italy
1PDF: 0 -
PO68 | RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CANCER AND MIGRAINE: A COHORT ANALYSIS AMONG DANISH NATIONAL HEALTH SURVEY PARTICIPANTS O. Rosenkrantz1, P. Szentkúti1, L. Amdisen1, E. Horváth-Puhó1, A.L. Pedersen1, H.E. Bøtker2, H. Elser1|3, J.P. Vandenbroucke1|4|5, H.T. Sørensen1 | 1Department of Clinical Epidemiology and Center for Population Medicine, Aarhus University Hospital and Aarhus University, Denmark; 2Department of Cardiology, Aarhus University Hospital, Department of Clinical Medicine, University of Aarhus, Denmark; 3Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; 4Department of Clinical Epidemiology, Leiden University Medical School Leiden, The Netherlands; 5School of Hygiene and Tropical Medicine, London, UK
2PDF: 0 -
PO67 | TARGETED THERAPIES FOR CANCER AND THE RISK OF ARTERIAL AND VENOUS THROMBOEMBOLISM O. Iqbal | Loyola University Stritch School of Medicine, Maywood, IL, USA
2PDF: 0 -
PO65 | OVARIC CANCER PRESENTING WITH COLD-AGGLUTININ MEDIATED HEMOLYTIC ANEMIA, PULMONARY THROMBOEMBOLISM AND DEEP VEIN THROMBOSIS R. Cannas | Hemostasis and thrombosis Center, Ospedale Santissima Trinità, ASL Cagliari, Italy
2PDF: 0 -
PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE T. Van Broeckhoven1|9, E. Van Gansewinkel5|10, J. De Bruijne2, F. Eskens3, D. De Groot4, K. Hermans5, N. Mohammad6, F. Van Vilsteren7, C. Verslype8, W. Moris9, M. Roest10, B. De Laat10 , J. De Vos-Geelen5, M. Kramer1|9 | 1Department of Gastroenterology and Hepatology, GROW – Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; 2Department of Gastroenterology & Hepatology, Utrecht University, University Medical Center Utrecht, The Netherlands; 3Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, the Netherlands; 4Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, the Netherlands; 5Department of Internal Medicine, Division of Medical Oncology, GROW – Research Institute for Oncology & Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; 6Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands; 7Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands; 8Digestive Oncology, University Hospitals Leuven, Belgium; 9Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands; 10Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands, on behalf of the Dutch Hepatocellular & Cholangiocarcinoma Group
2PDF: 0 -
PO62 | CLINICAL AND MOLECULAR DIAGNOSTIC CHALLENGES IN MYELOPROLIFERATIVE NEOPLASMS WITH LOW JAK2V617F ALLELIC BURDEN E. Morsia, D. Lame, M. Pianelli, G. Gramazio, R. Ceccarelli, I. Battilà, S. Rupoli, A. Poloni | Department of Clinical and Molecular Science, Università Politecnica delle Marche, Ancona, Italy
1PDF: 1 -
PO61 | RISK FACTORS FOR INTRACRANIAL HEMORRHAGE: AN UMBRELLA REVIEW TO INFORM MACHINE LEARNING PREDICTION MODELS IN GLIOMA PATIENTS RECEIVING ANTICOAGULATION T.A. Adeyemo, S. Greenley, F. Ware, W. Jones, A. Maraveyas, F. Haque | 1Centre of Excellence for Data Science, Artificial Intelligence and Modelling DAIM, Faculty of Science and Engineering, University of Hull, UK; 2Hull York Medical School, Hull, UK; 3Academic Library Services, University of Hull, UK; 4NHS Humber Health Partnership, Hull, UK
3PDF: 0 -
PO60 | VEXAS SYNDROME AS A NEW SEVERE THROMBOPHILIC CLONAL CONDITION: A SINGLE CENTRE EXPERIENCE C. Ambaglio1, E. Galimberti1, F. Schieppati1, M. Frigeni2, M. Marchetti1, L. Barcella1, A. Falanga 1|3 | 1Immunohematology and Transfusion Medicine Unit, ASST Papa Giovanni XXIII, Bergamo; 2Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo; 3School of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy
1PDF: 0 -
PO58 | TACKLING THE AWARENESS GAP IN CANCER-ASSOCIATED THROMBOSIS: IMPACT OF A BRIEF EDUCATIONAL INTERVENTION IN PATIENTS WITH GYNECOLOGICAL CANCERS P. Santini, F. Mancinetti, G. Fracassa, E. Fondi, E. Ianuà, A. D'Errico, M. Bigossi, C. Marchetti, V. Salutari, G. Scambia, C. Nero, R. Pola | Agostino Gemelli University Hospital Foundation IRCCS, Rome, Italy
1PDF: 0 -
PO57 | A NOVEL RISK ASSESSMENT MODEL FOR CANCER DETECTION WITHIN ONE YEAR AFTER INCIDENT VENOUS THROMBOEMBOLISM C. Antoun1, J. Hansen1|3, S. Brækkan1|3, C. Langholm1, N. Eide1, V. Morelli1|3, K. Hveem2 | 1Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø; 2HUNT Center for Molecular and Clinical Epidemiology, Norwegian University of Science and Technology, Trondheim; 3Thrombosis Research Center, Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
1PDF: 0 -
PO56 | EXTERNAL VALIDATION OF THE SAVED SCORE IN A CANADIAN REGIONAL CANCER CENTER COHORT: A REAL-WORLD ANALYSIS A. Naassan, R. Fatima, M. Naassan, C. Chisholm | Lakeridge Health, R.S. McLaughlin Durham Regional Cancer Centre, Department of Oncology, Oshawa, ON, Canada
5PDF: 0 -
PO55 | HISTORY OF CANCER IN PATIENTS WITH SEVERE HEREDITARY THROMBOPHILIA VERSUS NO THROMBOPHILIA: A SINGLE-CENTER COHORT OF PATIENTS WITH VENOUS THROMBOSIS A. Napolitano, E. Campello, C. Simion, G. Furlan, S. Gavasso, C. Bulato, C. Samà, S. Toffanin, B. Serena, L. Spiezia, P. Simioni | Internal Medicine 1 and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padova, Italy
1PDF: 0 -
PO54 | CANCER-ASSOCIATED THROMBOSIS IN ASPIRIN-TREATED PATIENTS AFTER ARTERIAL THROMBOSIS: THE COMPASS-ARTECAT-ASA PROSPECTIVE COHORT STUDY G. Gerotziafas1|3|4|5, S. Allakhverdieva6, P. Henrique Fernandes Do Carmo Las Casa1, P. Van Dreden1|2, J. Fareed3, N. Lomakin6 , I. Zotova6, L. Buryachkovskaya7 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France; 2Clinical Research, Diagnostica Stago, Gennevilliers, France; 3Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Chicago, USA; 4Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, The I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 5VAS-European Independent Foundation in Angiology/Vascular Medicine Milan, Italy; 6Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation, Moscow, Russia; 7Federal State Budgetary Institution «National Medical Research Centre of Cardiology Named After Academician E. I. Chazov» of the Ministry of Health of the Russian Federation, Moscow, Russia
1PDF: 0 -
PO53 | PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF REGN7508CAT FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) J. Zwicker1, M. P. O’Brien2, M. Carrier3, J. Connors4, A. Falanga5, A. Manzano6, R. Mcbane7, Y.Y. Janjigian1, G. O’Kane8, M. Onisko2, J. Kaplan2, A.P. Kithcart2, D.E. Gutstein2, A. Khorana9, M. F. Walsh2 | 1Memorial Sloan Kettering Cancer Center, New York, USA; 2Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 3University of Ottawa, Ottawa, ON, Canada; 4Harvard Medical School, Boston, MA, USA; 5Hospital Papa Giovanni XXIII, Bergamo, Italy; 6Hospital Universitario 12 de Octubre, Madrid, Spain; 7Mayo Clinic, Rochester, MN, USA; 8St. Vincent's University Hospital and School of Medicine, University College Dublin, Dublin, Ireland; 9James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
2PDF: 0 -
PO52 | MECHANISTIC POPULATION PHARMACOKINETIC/PHARMACODYNAMIC AND TIME-TO-EVENT MODELING SUPPORT SUSTAINED FACTOR XI INHIBITION AND SUPERIOR POST-OPERATIVE VENOUS THROMBOEMBOLISM PREVENTION WITH REGN7508CAT O. Milberg1, H. Abdallah1, R.K. Lokken2, R. Dingman1, K.A. Meagher1, P. Banerjee1, M.E. Burczynski1, E. Marin1, A.P. Kithcart1, D.E. Gutstein1 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Allucent, Cary, NC, USA
1PDF: 0 -
PO51 | MECHANISTIC POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF FACTOR XI-TARGETING MONOCLONAL ANTIBODIES SUPPORTS DURABLE ANTICOAGULANT COVERAGE AND TRANSLATIONAL DOSE AND REGIMEN SELECTION O. Milberg1, H. Abdallah1, R.K. Lokken2, R. Dingman1, K.A. Meagher1, M.E. Burczynski1, E. Marin1, A.P. Kithcart1, D. E. Gutstein1 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Allucent, Cary, NC, USA
1PDF: 1 -
PO50 | SUB-ANALYSIS OF INTERIM RESULTS FROM A PHASE 2 STUDY INVESTIGATING REGN9933A2 AND REGN7508CAT FOR THE PREVENTION OF CONTACT-MEDIATED VENOUS THROMBOEMBOLISM IN PATIENTS WITH ACTIVE CANCER UNDERGOING PERIPHERALLY INSERTED CENTRAL CATHETER PLACEMENT (ROXI-CATH) J. Zwicker1,2, A.P. Kithcart3, J. Kaplan3, Y-C. Cheng3, J.G. Raya3, J. Xiao3, S. Li3, K. Musgrave4, D.E. Gutstein3, G. Piazza5 | 1Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Weill Cornell Medical Center, New York, NY, USA; 3Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 4Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; 5Brigham and Women’s Hospital, Boston, MA, USA
1PDF: 0 -
PO49 | PROPHYLACTIC ANTICOAGULATION DECISIONS IN HIGH-RISK PATIENTS RECEIVING CANCER-DIRECTED THERAPY: ANALYSIS OF THE VERMONT METHOD J. Barker1, K. Libby1, C. Holmes2, K. Martin2 | 1University of Vermont Health System; 2Department of Medicine, University of Vermont, Burlington, VT, USA
2PDF: 0 -
PO47 | VENOUS THROMBOEMBOLISM IN BREAST CANCER: INSIGHTS FROM A SINGLE-CENTER COHORT S. Kozhukhov, N. Dovganych | SI “NSC “The M. D. Strazhesko Institute of Cardiology, Clinical and Regenerative Medicine of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine; 2Cardio-Oncology Center, Kyiv, Ukraine
1PDF: 0 -
PO45 | KHORANA RISK SCORE AND GENOMIC PROFILING FOR PREDICTION OF VENOUS THROMBOEMBOLISM IN OVARIAN CANCER P. Santini, L. Mastrantoni, G. Anderson, F. Camarda, I. Marino, J. Preziosi, M. Buttarelli, M. Manfredelli, A. Minucci, F. Persiani, L. Giacò, T. Pasciuto, I. Conti, I. Mozzetta, F. Mancinetti, S. M. P. D’Ambrosio, M. Bigossi, C. Marchetti, V. Salutari, G. Scambia, C. Nero, R. Pola | Agostino Gemelli University Hospital Foundation IRCCS, Rome, Italy
1PDF: 0 -
PO44 | PREDICTORS OF ONE-YEAR MORTALITY IN NEWLY DIAGNOSED METASTATIC BREAST CANCER: THE PROGNOSTIC ROLE OF HEMOSTATIC BIOMARKERS AND EARLY THROMBOEMBOLISM M. Marchetti1|2|3, P. Gomez-Rosas1|4|5, S. Bolognini1, C. Ticozzi1, D. Romeo1, F. Schieppati1|3, L. Barcella1|3, F. Petrelli6, A. D'Alessio7, R. Labianca7, A. Falanga1|2|3 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; 3ERN EuroBloodNet; 4Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands; 5Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; 6Oncology Unit, Hospital Treviglio-Caravaggio, Treviglio, Italy; 7Fondazione ARTET Onlus, Bergamo, Italy; *On behalf of the Hypercan Investigators
0PDF: 0 -
PO43 | ELEVATED CIRCULATING TISSUE PLASMINOGEN ACTIVATOR LEVELS PREDICT GASTROINTESTINAL AND BREAST CANCER RISK: A PROSPECTIVE NESTED CASE-COHORT STUDY S. Bolognini1|2, C. Ticozzi1, P. Gomez-Rosas1|3, F. Schieppati1|2, G. Sampietro4, L. Barcella1, M. Marchetti1|2, A. Falanga1|2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands; 4Unit of Epidemiology and Statistics, ATS Bergamo, Italy
1PDF: 0 -
PO42 | DIFFERENTIAL EXPRESSION OF HEMOSTATIC BIOMARKERS ACROSS CANCER TYPE AND DISEASE STAGE: A PROSPECTIVE ANALYSIS OF 4,292 PATIENTS FROM THE HYPERCAN STUDY P. Gómez-Rosas1|2|, D. Romeo1, S. Bolognini1, C. Ticozzi1, F. Schieppati1, A. D’Alessio4, R. Labianca4, A. Falanga1|5|6, M. Marchetti1|5|6 | 1Hospital Papa Giovanni XXIII, Bergamo, Italy; 2Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands; 3Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; 4Fondazione ARTET Onlus, Bergamo, Italy; 5ERN EuroBloodNet; 6School of Medicine and Surgery, University of Milan Bicocca, Italy; *On Behalf Of The Hypercan Investigators
1PDF: 0 -
PO41 | VENOUS THROMBOEMBOLISM IN PERIPHERAL BLOOD STEM CELL COLLECTION. A SINGLE CENTER EXPERIENCE P. Holly1, J. Hudecek1, J. Chudej1, L. Valekova1, I. Plamenova1, E. Flochova1, R. Simonova1, J. Sokol1, J. Stasko1, M. Pietrzykova1|2, E. Vescecikova2 | 1Department of Hematology and Transfusion Medicine, University Hospital in Martin, Martin, Slovakia; 2National Transfusion Service, Martin, Slovakia
1PDF: 0 -
PO40 | RADAR, UK-MRA MYELOMA XV - COMPARING MRD-GUIDED TREATMENT ESCALATION AND DE-ESCALATION STRATEGIES IN PATIENTS WITH NEWLY DIAGNOSED MYELOMA SUITABLE FOR STEM CELL TRANSPLANTATION: THROMBOPROPHYLAXIS SUBGROUP STUDY PROTOCOL Z. Sayar, on behalf of the RADAR Investigators | Whittington Health NHS Trust and Royal Free Hospital, London, UK
1PDF: 0 -
PO39 | RISK OF VENOUS THROMBOEMBOLISM ASSOCIATED WITH PERIPHERALLY INSERTED CENTRAL CATHETERS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY: A REAL-WORLD SINGLE-CENTRE EXPERIENCE S. Gilani, H. Rubbani, A. Mackie | Cancer Centre, University Hospitals of North Midlands, Staffordshire, UK
1PDF: 0 -
PO38 | PERICATHETER AND SYSTEMIC THROMBOSIS DURING CAR-T LYMPHOCYTAPHERESIS: INCIDENCE AND CLINICAL CORRELATES I. Pansini1|2, E. Galli1, A. Corrente2, N. Piccirillo1|2, M. Viscovo1|2, S. Hohaus1|2, P. Chiusolo1|2, F. Sorà1|2, S. Sica1|2 | 1Department of Laboratory and Hematologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; 2Hematology Section, Department of Radiologic and Hematologic Sciences, Università Cattolica del Sacro Cuore, Rome, Italy
0PDF: 0 -
PO37 | CLINICAL SIGNIFICANCE OF SYMPTOMATIC AND INCIDENTAL VENOUS THROMBOEMBOLISM IN CANCER PATIENTS TREATED WITH APIXABAN P. Hussaini1, T.L. Larsen2, W. Ghanima1|3, A.E.A. Dahm1|2 | 1Institute of Clinical Medicine, University of Oslo, Oslo, Norway; 2Department of Hematology, Akershus University Hospital; Lørenskog, Norway; 3Clinic of Internal Medicine, Østfold Hospital, Grålum, Norway
1PDF: 0 -
PO36 | EXTENDED DURATION REDUCED DOSE ANTICOAGULATION IN CANCER-ASSOCIATED THROMBOSIS: A REAL-WORLD COHORT WITH LONG TERM FOLLOW UP A. Bhide1, I. Welding1, O. Ogunbiyi1, S. Hawkins2, E. Greenlay1, N. Prasannan1, J. Westwood1, M. Thomas1 | 1Department of Clinical Haematology, University College London Hospital, London; 2Data Clinic, University College London, UK; A. Bhide and I. Welding joint First Authors
1PDF: 0 -
PO35 | A MULTICENTRE AUDIT OF CURRENT TUMOUR THROMBOSIS MANAGEMENT IN THE UNITED KINGDOM A.A. Bhatti1, L. Tafesh1, A. Waton1, M. Thomas3, N. Prasannan3, A. Bhide3, R. Walsh3, T. Lucas3, K. White4, T. Bariana4, O. Tsiamita4, S. Soman4, P. Woolley5, I. Lacej5, K. Musgrave1|2 | 1Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; 2Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; 3University College London Hospitals NHS Foundation Trust, London, UK; 4Barts Health NHS Trust, London, UK; 5Imperial College Healthcare NHS Trust, London, UK
1PDF: 0 -
PO34 | INVESTIGATORS’ DECISIONS ON ANTICOAGULATION AFTER EXTENDED API-CAT TREATMENT FOR CANCER VENOUS THROMBOEMBOLISM I. Mahé1|4, F. Happe2, M. Monreal5|7, H. Robert-Ebadi8, P. Debourdeau9, J. R. Fabreguettes10, S. Accassat11, P. Mismetti4|11|12, P. Girard13, S. Laporte4|12|14, C. Chapelle14 | 1Paris Cité University; 2Assistance Publique - Hôpitaux de Paris, Louis Mourier Hospital, Department of Internal Medicine; 3Inserm UMR-S970, Paris Cardiovascular Research Center, Team « Endotheliopathy and Hemostasis Disorders », Paris, France; 4F-CRIN INNOVTE Network, France; 5Department of Internal Medicine, Institut de Recerca Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 6Department of Medicine, Universitat Autonoma de Barcelona, Barcelona; 7Universidad Catolica San Antonio de Murcia, Murcia, Spain; 8Division of Angiology and Hemostasis, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland; 9Arles Hospital, Oncology unit, Arles, France; 10Assistance Publique - Hôpitaux de Paris, AGEPS, France; 11Service de Médecine Vasculaire et Therapeutique, CHU de Saint-Etienne, Saint-Etienne, France; 12Université Jean Monnet, Mines Saint-Étienne, INSERM Unité 1059, Santé Ingénierie Biologie Saint-Étienne SAINBIOSE, Saint-Étienne, France; 13Département de Pneumologie, Institut Mutualiste Montsouris, Paris; 14Service de Pharmacologie Clinique, CHU de Saint-Etienne, Saint-Etienne, France
2PDF: 0 -
PO32 | ANTICOAGULANT THROMBOPROPHYLAXIS IN AGGRESSIVE LYMPHOMAS PATIENTS: PREDICTIVE THROMBOTIC RISK SCORES AND RISK FACTORS L. Gurgoglione1, G. Gini1, S. Rupoli1, A. Poloni1|2 | 1Hematology, AOU delle Marche, Ancona; 2Università Politecnica delle Marche, Ancona, Italy
1PDF: 0 -
PO31 | MIGRATORY SUPERFICIAL THROMBOPHLEBITIS REFRACTORY TO APIXABAN IN A PATIENT WITH LUNG ADENOCARCINOMA I. Goldberg1|2, P. Raanani1|2|3, G. Spectre1|2 | 1Institute of Hematology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel; 2Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; 3Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel
1PDF: 0 -
PO30 | LONG-TERM ANTICOAGULANT THERAPY AND PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM IN ADVANCED OVARIAN CANCER V. Bitsadze 1, A. Vorobev 1, J. Khizroeva 1, A. Solopova 1, M. Tretyakova 1, N. Gashimova 1, K. Grigoreva 1, A. Khisamieva 1, J. Gris 1|2, I. Elalamy1|3|4, G. Gerotziafas1|3|4, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 2Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 3Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 4Hospital Tenon, Paris, France
1PDF: 0 -
PO29 | CANADIAN INSIGHTS INTO THE MANAGEMENT OF BREAKTHROUGH THROMBOSIS S. Ramdani1, C. Séguin2 | 1Division of Hematology, Post-Graduate Medical Education Program, McGill University, Montreal; 2Division of Hematology, Department of Medicine, McGill University Health Center, Montreal, Canada
1PDF: 1 -
PO28 | CLINICAL IMPLICATIONS OF ANTICOAGULANT DRUG INTERACTIONS WITH TARGETED AND IMMUNE THERAPIES IN ONCOLOGY: A CONTEMPORARY RISK STRATIFICATION FRAMEWORK D. Dhami1, C. Solowiej Singh 1, M. Dhami 2 | 1Abrazo Internal Medicine Residency; 2Eastern Connecticut Hematology Oncology, Norwich, CT, USA
1PDF: 0 -
PO27 | URINE QUALITATIVE ASSESSMENT OF DIRECT ORAL ANTICOAGULANTS IN ROUTINE CLINICAL PRACTICE F. Schieppati1|2, P. Gomez-Rosas1|3, C. Ambaglio1, V. Brusegan1, O.C. Cretu1, E. Galimberti1, F. Zunino1, L. Barcella1, J. Harenberg4|5, A. Falanga1|2, M. Marchetti1|2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; 4Ruprecht Karls University of Heidelberg, Heidelberg, Germany; 5DOASENSE GmbH, Heidelberg, Germany
2PDF: 0 -
PO26 | OUTCOMES OF DIRECT ORAL ANTICOAGULANTS IN UNUSUAL-SITE THROMBOSIS: IMPACT OF ACTIVE CANCER S. Guglielmo1, M. Lovisotto1, L. Scarano1, E. De Bon2, S. Barbar2 | 1Internal Medicine, Department of Medicine, Azienda Ulss 6 Euganea, Cittadella (PD), Italy; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda Ulss 6 Euganea, Cittadella (PD), Italy
1PDF: 0 -
PO25 | EVOLUTION OF ANTICOAGULANT STRATEGIES AND CLINICAL OUTCOMES IN CANCER-ASSOCIATED THROMBOSIS: A LONGITUDINAL ANALYSIS OF THE START2 REGISTRY ONCO-VTE M. Marchetti1|2, T. Zollner1|2, OC. Cretu1|2, A. Chistolini3, R. Pancani4, L. Puccetti5, P. Sivera6, W. Ageno7, G. Elmi8, V. Fregoni9, V. Tonelli10, E. Antonucci11, D. Poli11|12, A. Falanga1|2, L. Barcella1|2 | 1Hemostasis & Thrombosis Center, Department of Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo Italy; 2ERN EuroBloodNet; 3Hematology Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; 4Pulmonary Unit, Hospital of Siena, University of Siena, Siena, Italy; 5Hemostasis and Thrombosis Unit, Hospital of Siena, University of Siena, Siena, Italy; 6Haematology Unit, Ordine Mauriziano Hospital, Turin, Italy; 7Department of Medicine, University of Padua, Padua, Italy; 8Department of Medicine, Maggiore Hospital, Bologna, Italy; 9Department of Medicine, Sondalo Hospital, Sondalo, Italy; 10Angiology Unit, Sant'Eugenio Hospital, Rome, Italy; 11Arianna Anticoagulazione Foundation, Bologna, Italy; 12Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
1PDF: 0 -
PO24 | WE ARE JUGGLING MANY POSSIBILITIES: HEALTHCARE PROFESSIONALS’ EXPERIENCES AND PERSPECTIVES ON INTERPRETATION OF PULMONARY EMBOLISM SIGNS AND SYMPTOMS IN PATIENTS WITH LUNG CANCER A.A. Højen1, M. Søgaard1, A.G. Ording1, M.R. Saugbjerg2, T.D. Christensen2|3, H.R. Jacobsen4, L. Jørgensen5, H. Enggaard5 | 1Danish Center for Health Services Research, Aalborg University Hospital; 2Department of Cardiothoracic Surgery, Aarhus University Hospital; 3Department of Clinical Medicine, Aarhus University Hospital; 4Department of Oncology, Aalborg University Hospital; 5Clinical Nursing Research Unit, Aalborg University Hospital, Denmark
3PDF: 0 -
PO23 | IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA RELATED TO DELAYED IMMUNE CHECKPOINT INHIBITORS TOXICITY: A CASE REPORT E. Galimberti1, F. Schieppati1, C. Ambaglio1, M. Marchetti1, L. Barcella1, A. Falanga1|2 | 1Immunohematology and Transfusion Medicine Unit, ASST Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy
1PDF: 0 -
PO22 | LONG-TERM ANTICOAGULANT THERAPY AND REDUCTION OF OVARIAN CANCER RECURRENCE: CLINICAL EVIDENCE OF A POTENTIAL ANTITUMOUR EFFECT J. Khizroeva1, V. Bitsadze1, A. Vorobev1, A. Solopova1, M. Tretyakova1, N. Gashimova1, K. Grigoreva1, A. Khisamieva1, J. Gris1|2, I. Elalamy1|3|4, G. Gerotziafas1|3|4, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University, Moscow, Russia; 2Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 3Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 4Hospital Tenon, Paris, France
2PDF: 0 -
PO21 | PSYCHOLOGICAL IMPACT OF CANCER-ASSOCIATED THROMBOSIS: DUAL BURDEN AND IMPLICATIONS FOR QUALITY OF LIFE AND INTEGRATED PATIENT-CENTERED CARE G. Gerotziafas1|4, Y. Mitrou5, M. Marchetti6, P. Las Casa1, A. Tafur7, V. Bitsadze3, J. Khizroeva3, D. Taizhanova8, D. Antic9, C. Frére10, A. Makatsariya3, L. Garderet1|11, A. Escargueil1, C. Ay12, N. Lomatkin13, Z. Tazi-Mezalek14, M. Sassi15, M. Catalano4|16, J. Gligorov1|17, J. Caprini18, P. Van Dreden1|19, J. Fareed2, A. Falanga6 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP)Paris France; 2Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Chicago, USA; 3Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, The I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 4VAS-European Independent Foundation in Angiology/Vascular Medicine Milan Italy; 5Department of Phylosophy, National and Kapodistrian University of Athens, Greece; 6Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy. School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; 7Vascular Medicine, Endeavor Health, Evanston, IL, USA; Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA; 8Department of Internal Diseases, Karaganda Medical University Non-Commercial Joint Stock Company, Karaganda, Kazakhstan; 9Clinic for Hematology, University Clinical Center of Serbia, Faculty of Medicine University of Belgrade Belgrade Serbia; 10Department of Hematology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, INSERM UMRS-1166 Institute of Cardiometabolism and Nutrition, Paris, France; 11Clinical Haematology Department, Sorbonne Université, Pitié-Salpêtrière Hospital, APHP, Paris; 12Department of Internal Medicine I, Clinical Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria; 13Cardiology Division, Central Clinical Hospital of Presidential Administration, Moscow, Russia; 14Department of Internal Medicine, Hématologie Clinique, Centre Hospitalo-Universitaire Ibn Sina, Université Mohammed V de Rabat, Rabat, Morocco; 15Hematology Laboratory of Maternity and Neonatal Center of Monastir, Faculty of Pharmacy of Monastir, Monastir, Tunisia; 16Inter-University Research Center on Vascular Diseases, University of Milan-L Sacco Hospital, Milan, Italy; 17Medical Oncology Department, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, Paris, France; 18Vascular Surgery, Pritzker School of Medicine at the University of Chicago, Chicago, USA; 19Clinical Research, Diagnostica Stago, Gennevilliers, France
1PDF: 0 -
PO20 | DYSFUNCTION OF THE ADAMTS-13/VON WILLEBRAND FACTOR AXIS, MEDIATED BY NETOSIS, AS A DRIVER OF PROTHROMBOTIC STATE AND UNFAVORABLE PROGNOSIS IN ONCOGYNECOLOGICAL PATIENTS V. Bitsadze1, E. Beloborodova2, J. Khizroeva1, A. Solopova1, M. Tretyakova1, N. Gashimova1, K. Grigoreva1, A. Tatarintseva1, J. Christophe Gris1|3, I. Elalamy1|4|5, G. Gerotziafas1|4|5, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 2Clinic MEDSI Network of Medical Centers in Moscow, Russia; 3Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 4Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 5Hospital Tenon, Paris, France
1PDF: 0 -
PO19 | THE INTER-RELATIONSHIP BETWEEN NETOSIS, THE ADAMTS-13/VWF AXIS, AND HEMOSTATIC ACTIVATION IN PATIENTS WITH GYNECOLOGICAL MALIGNANCIES: PROGNOSTIC SIGNIFICANCE AND IMPACT OF CHEMOTHERAPY A. Makatsariya1, E. Beloborodova2,V. Bitsadze1, J. Khizroeva1, A. Vorobev1, A. Solopova1, M. Tretyakova1, N. Gashimova1, K. Grigoreva1, A. Oskolkova1, J. Christophe Gris1|3, I. Elalamy1|4|5, G. Gerotziafas1|4|5 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University Sechenov University, Moscow, Russia; 2MEDSI Network of Medical Centers, Moscow, Russia; 3Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 4Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 5Hospital Tenon, Paris, France
1PDF: 0 -
PO18 | THE THROMBO-INFLAMMATION AXIS AS PREDICTOR OF TOXICITY IN PATIENTS TREATED WITH CAR-T CELLS C. Fernández-Arias1, M. Marcos-Jubilar1, M. Panizo1, C. Vázquez-Puerta2, J.R. González-Porras2, M. Ibáñez1, A. Queralt1, M. Carrasco1, M.B. Villacrés1, C. Conde1, P. Elizalde1, S. Huerga1, A. Alfonso1, P. Rodríguez-Otero1, S. Villar1, M.A. Canales1, J. Rifón1, F. Prósper1, J.A. Páramo1, J. Orbe1, R. Lecumberri1 | 1Clínica Universidad de Navarra, Pamplona; 2Hospital Clínico Universitario de Salamanca, Salamanca, Spain
2PDF: 0 -
PO17 | PREDICTIVE VALUE OF INFLAMMATORY AND ENDOTHELIAL BIOMARKERS FOR CANCER RISK IN HEALTHY INDIVIDUALS: EVIDENCE FROM THE HYPERCAN STUDY C. Ticozzi1, S. Bolognini1|2, P. Gomez-Rosas1|3, F. Schieppati1|2, G. Sampietro4, L. Barcella1, M. Marchetti1|2, A. Falanga1|2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands; 4Unit of Epidemiology and Statistics, ATS Bergamo, Italy
1PDF: 0 -
PO16 | EPIDEMIOLOGY, CLINICAL CHARACTERISTICS, AND OUTCOMES OF PROVOKED AND UNPROVOKED PULMONARY EMBOLISM IN A MULTICULTURAL ISRAELI POPULATION R. Farah1, N.L. Bragazzi2|3|4, H.İ. Ceylan5, Ł. Szarpak6|7|8|9, W. Mahajni1, N. Ashqar1, A. M. Fioretti10, R. Khamisy-Farah11 | 1Internal Medicine B Department, Ziv Medical Center, Azrieli Faculty of Medicine, Bar-Ilan University, Galilee, Safed, Israel; 2Laboratory for Industrial and Applied Mathematics, Department of Mathematics and Statistics, York University, Toronto, Canada; 3Postgraduate School of Public Health, Department of Health Sciences, University of Genoa, Italy; 4UNESCO Chair, Health Anthropology, Biosphere and Healing Systems, University of Genoa, Italy; 5Physical Education and Sports Teaching Department, Faculty of Sports Sciences, Atatürk University, Erzurum, Turkey; 6Department of Clinical Research and Development, LUXMED Group, Warsaw, Poland; 7Institute of Medical Science, Collegium Medicum, The John Paul II Catholic University of Lublin, Lublin, Poland; 8The World Academic Council of Emergency Medicine, Sarasota, FL, USA; 9Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, USA; 10Cardio-Oncology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, Italy; 11Clalit Health Service, Azrieli Faculty of Medicine, Bar-Ilan University, Galilee, Safed, Israel
1PDF: 0 -
PO14 | SYMPTOM BURDEN IN PATIENTS WITH CANCER AND THROMBOEMBOLISM: A POPULATION-BASED MATCHED COHORT STUDY D. Siegal1|2, Z. O’Neill1|2, L. Nguyen3, N. Liu3, M. Carrier1|2, R. Sutradhar3|4 | 1Ottawa Hospital Research Institute, Ottawa; 2Department of Medicine, University of Ottawa, Ottawa; 3ICES, Toronto, Canada; 4Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
1PDF: 0 -
PO13 | OUTPATIENT TREATMENT OF VENOUS THROMBOEMBOLISM AND SUBSEQUENT RISK OF CANCER S. Sørensen, D. Farkas, H. Sørensen | Department of Clinical Epidemiology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark
1PDF: 0 -
PO12 | IMPACT OF INHERITED THROMBOPHILIA ON CANCER-ASSOCIATED THROMBOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS E. Campello1, G. Furlan1, A. Boccatonda2, A. Napolitano1, C. Simion1, P. Simioni1 | 1Internal Medicine 1 and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padova, Italy; 2Diagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy
2PDF: 0 -
PO11 | THROMBOEMBOLIC EVENTS DURING PERIOPERATIVE THERAPY FOR RESECTABLE AND BORDERLINE RESECTABLE PANCREATIC CANCER IN THE PREOPANC-2 TRIAL R.A.L. Willems1|5, A.E. Van Diepen1|2|6, EN. Dekker7, Q.P. Janssen7, J.L. Van Dam7, N. Michiels8, C.W.F. Van Eijck9, K.E.P.E. Hermans1|2, B.A. Bonsing8, K.P. Bosscha10, S.A.W. Bouwense11|12, O. R. Busch13|14, H. Ten Cate4|5|15|16, P.P.L.O. Coene17, C.H.J. Van Eijck7, N. Van Es18|19, E. Van Der Harst17, I.H.J.T. De Hingh20, T.M. Karsten21, G. Kazemier13|14, M.B. Van Der Kolk22, B. De Laat3|5, M.S.L. Liem22, J.S.D. Mieog8, V.B. Nieuwenhuijs24, G.A. Patijn24, M. Roest3, H.C. Van Santvoort25, L. Valkenburg-Van Iersel1|2, R. F. De Wilde7, F. Wit26, B.M. Zonderhuis13|14, M.G. Besselink13|14, M.Y.V. Homs6, G. Van Tienhoven14|27, J. W. Wilmink14|28, B. Groot Koerkamp7, J. De Vos-Geelen1|2 | 1Maastricht University Medical Center, Department of Internal Medicine, Division of Medical Oncology; 2GROW – Research Institute for Oncology & Reproduction, Maastricht University, Maastricht; 3Synapse Research Institute, Department of Functional Coagulation, Maastricht; 4Maastricht University Medical Center, Thrombosis Expert Center Maastricht, Maastricht; 5Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, Maastricht; 6Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam; 7Erasmus MC Cancer Institute Rotterdam, University Medical Center Rotterdam, Department of Surgery; 8Leiden University Medical Center, Department of Surgery, Leiden; 9Solid Tumour Immunology Research Rotterdam (STIRR), Department of Pulmonary Medicine, Erasmus University Medical Centre, Rotterdam; 10Jeroen Bosch Hospital, Department of Surgery, Den Bosch; 11Maastricht University Medical Center, Department of Surgery, Maastricht; 12Maastricht University Medical Center, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht; 13Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam; 14Cancer Center Amsterdam; 15Maastricht University Medical Center, Department of Internal Medicine, Division Vascular Medicine, Maastricht; 16Maastricht University, Department of Biochemistry, Laboratory for Clinical Thrombosis and Hemostasis, Maastricht; 17Maasstad Hospital, Department of Surgery, Rotterdam; 18Amsterdam UMC, location University of Amsterdam, Department of Vascular Medicine, Amsterdam; 19Amsterdam UMC, location University of Amsterdam, Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam; 20Catharina Hospital, Department of Surgery, Eindhoven; 21OLVG, Department of Surgery, Amsterdam; 22Radboud University Medical Center, Department of Surgery, Nijmegen; 23Medisch Spectrum Twente, Department of Surgery, Enschede; 24Isala Oncology Center, Department of Surgery, Zwolle; 25Regional Academic Cancer Center Utrecht, St. Antonius Hospital and University Medical Center Utrecht, Department of Surgery, Utrecht; 26Frisius MC, location Leeuwarden, Department of Surgery, Leeuwarden; 27Amsterdam UMC, location University of Amsterdam, Department of Radiation Oncology, Amsterdam; 28Amsterdam UMC, location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands
3PDF: 0 -
PO10 | RISK OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS WITH CENTRAL VENOUS CATHETERS: RESULTS FROM THE VIENNA CAT-BLED STUDY B. Sunder-Plassmann 1, N, Vladic1, C. Englisch1, F. Moik1|3, V. Sunder-Plassmann2, A. Berghoff2, M. Preusser2, I. Pabinger1, C. Ay1 | 1Division of Hematology and Haemostaseology, Department of Medicine I, Medical University of Vienna; Vienna, Austria; 2Division of Oncology, Department of Medicine I, Medical University of Vienna; Vienna, Austria; 3Division of Oncology, Department of Internal Medicine, Medical University of Graz; Graz, Austria
1PDF: 0 -
PO09 | CANCER MORTALITY AFTER INCIDENT VENOUS THROMBOEMBOLISM C. Langholm1, N.H. Eide1, K. Hveem2|3|4, N. Van Es5|6, V.M. Morelli1|7, S.K. Braekkan1|7, J.B. Hansen1|7 | 1Thrombosis Research Group, Department of Clinical Medicine, UiT – The Arctic University of Norway, Tromsø, Norway; 2HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger, Norway; 3HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway; 4Department of Research, St. Olav University Hospital, Trondheim, Norway; 5Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; 6Amsterdam Cardiovascular Sciences Pulmonary Hypertension and Thrombosis Amsterdam, the Netherlands; 7Thrombosis Research Center, Department of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
1PDF: 0 -
PO08 | NEXT-GENERATION THROMBOLYTICS: ENGINEERING STREPTOKINASE FOR ENHANCED ACTIVITY AND REDUCED IMMUNOGENICITY M. Kanwal1|2 | 1Consiglio Nazionale delle Ricerche, Naples, Italy; 2Department of Environmental, Biological and Chemical Sciences and Technologies, University of Campania "Luigi Vanvitelli", Italy
1PDF: 0 -
PO07 | PLATELET INHIBITION BY THE NOVEL NITRIC OXIDE-DONOR NITROSOOXYPROPANOL M. Lindkvist, J. Jakobsson, F. Lynfeldt, B. Sandberg, K. Fransén, K. Nilsson, M. Grenegård | Cardiovascular Research Centre, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
1PDF: 1 -
PO06 | ACTIVATED PLATELETS INDUCE THE FORMATION OF NEUTROPHIL EXTRACELLULAR TRAPS VIA TOLL-LIKE RECEPTOR-4 AND P-SELECTIN GLYCOPROTEIN LIGAND-1 I.C. Moschonas, A.D. Tselepis | Atherothrombosis Research Centre, University of Ioannina, Greece
2PDF: 0 -
PO05 | DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF NOVEL IMATINIB AND NILOTINIB ANALOGUES EXPRESSING ENHANCED ANTIPLATELET AND ANTICANCER ACTIVITIES D. Pantazi1, L. Pechlivani1, A. Kosma1, K. Lalechou1, M.G. Siskos2, D. Alivertis3, A.D. Tselepis1 | 1Atherothrombosis Research Centre, Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Greece; 2Laboratory of Organic Chemistry, Department of Chemistry, University of Ioannina, Greece; 3Department of Biological Applications and Technology, University of Ioannina, Greece
2PDF: 0 -
PO04 | FIBRIN CLOT SHIELDS PROMOTE CLONAL SELECTION IN CANCER CELLS: PROCOAGULANT ACTIVITY AND SURVIVAL OF CLOT-EMBEDDED CELLS. A NOVEL TUMOR MICROENVIRONMENT MODEL M.A. Baghdadi1|2, E. Mbemba1, P. Las Casa1, P. Van Dreden1|3, N. Saleem1|4, J. Fareed4, P. Kempaiah4, M. Sabbah1, G. Gerotziafas1|4 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology, Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP) Paris, France; 2Research Center, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia; 3Diagnostica Stago, Gennevilliers, France; 4Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Ill., USA
2PDF: 0 -
PO03 | HEPATIC FIBROSIS–DRIVEN TISSUE FACTOR EXPRESSION BY MALIGNANT CHOLANGIOCYTES IS ASSOCIATED WITH CANCER-ASSOCIATED THROMBOSIS AND POOR SURVIVAL IN INTRAHEPATIC CHOLANGIOCARCINOMA L. Fabris1|2|3, Y. Frión-Herrera1, C. Venturin1|3, M. Cadamuro4, J. Gasparello5, C. M. Radu1|2, M. Fassan1|5, C. Mescoli6, U. Cillo7|8, E. Gringeri7|8, G. Zanus7|9, E. Campello1|2, M. Strazzabosco3, P. Simioni1|2 | 1Department of Medicine, University of Padua; 2Clinical Medicine 1 and Thrombotic and Haemorrhagic Disease Unit, and Haemophilia Center, Padua University-Hospital; 3Department of Internal Medicine, Digestive Disease Section, Liver Center, Yale University, New Haven, CT, USA; 4School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy; 5Pathology Unit, Ca' Foncello Hospital, ULSS2 Marca Trevigiana, Treviso; 6Pathology Unit, Padua University-Hospital; 7Department of Surgery, Oncology and Gastroenterology, University of Padua; 8Hepatobiliary Surgery and Liver Transplantation Unit, Padua University-Hospital; 9General Surgery Unit, Ca' Foncello Hospital, ULSS2 Marca Trevigiana, Treviso, Italy
1PDF: 0 -
PO02 | SYNERGISTIC INTERACTION OF ENDOTHELIAL AND CANCER CELLS IN THE FORMATION AND STRUCTURE OF THE FIBRIN CLOT SHIELDS M.A. Baghdadi1|2, E. Mbemba1, P. Las Casa1, P. Van Dreden1|3, N. Saleem1|4, J. Fareed4, P. Kempaiah4, M. Sabbah1, G. Gerotziafas1|4 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP) Paris France; 2Research Center, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia; 3Diagnostica Stago, clinical research, Gennevilliers, France; 4Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Ill., USA
3PDF: 1 -
PO01 | MELANOMA-DERIVED EXTRACELLULAR VESICLES DRIVE VON WILLEBRAND FACTOR–DEPENDENT THROMBOSIS AND METASTASIS Y. Wang1|2, X. Liu1, T. Downar3, A. Topuz4, A. Bauer1, J. Kött1|5, K. Nekipelov6, S. Brenna7, G. Bendas6, B. Puig7, S. Schneider1, D. Fedosov4, C. Gorzelanny1 | 1Department of Dermatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 2Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 3Experimental Dermatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; 4Institute for Advanced Simulation (IAS-2), Forschungszentrum Jülich, Jülich, Germany; 5Fleur Hiege Center for Skin Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 6Pharmaceutical Institute, University of Bonn, Bonn, Germany; 7Neurology Department, Experimental Research in Stroke and Inflammation (ERSI), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
1PDF: 0 -
OC13 | VON WILLEBRAND FACTOR PREDICTS POOR OUTCOME IN PANCREATIC CANCER AND MEDIATES TUMOR-ENDOTHELIUM INTERACTIONS FACILITATING METASTASIS B. Ünlü1, Z. Zhao1, N. Joshi1, S. De1, A. Chion1, I. Schoen1, J. O’Donnell1, M. Flick2, M. Fishel3|4, J. O’Sullivan1 | 1School of Pharmacy and Biomolecular Sciences, Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, Dublin, Ireland; 2UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, USA; 3IU Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA; 4Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
1PDF: 0 -
OC12 | RISK OF VENOUS THROMBOEMBOLISM AFTER REMOVAL OF AN UPPER EXTREMITY CENTRAL CATHETER ASSOCIATED WITH A DEEP VEIN THROMBOSIS IN CANCER PATIENTS M. Sartori, A. Trentini, S. Cavara, E. Favaretto, M. Soldati, B. Cosmi | Angiology and Blood Coagulation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
1PDF: 0 -
OC11 | COMPLEXITIES IN MANAGING ANTITHROMBOTIC THERAPY IN PATIENTS WITH CANCER APPROACHING END-OF-LIFE: A MIXED METHOD INTEGRATION USING JOINT DISPLAY ANALYSIS E. Baddeley1, L. Van’t Walderveen2, H. Enggaard3, M. Søgaard4, D. Abbel2, S. Cannegieter2, M. Edwards1, C. Font5, J. Goedegebuur2, F.A. Klok2, K.J. Lifford1, I. Mahé6, S.P. Mooijaart2, S.I.R. Noble1, M. Pearson7, K. Seddon1, S. Sivell1, S. Szmit8, S Trompet2, A.A. Højen4 | 1Cardiff University, Cardiff, UK; 2Leiden University Medical Center, Leiden, The Netherlands; 3Aalborg University Hospital, Aalborg, Denmark; 4Aalborg University and Aalborg University Hospital, Aalborg, Denmark; 5Hospital Clinic Barcelona, Barcelona, Spain; 6Paris Cité Université, Paris, France; 7Hull York Medical School, Hull, UK; 8Centre of Postgraduate Medical Education, Warsaw, Poland
1PDF: 0 -
OC10 | FROM DESIGN TO CLINICAL PHASE 3 IN ONCOLOGY: CD13-TARGETED TISSUE FACTOR AND TUMOR INFARCTION W.E. Berdel, C. Schwöppe, C. Brand, K. Hessling, A.F. Berdel, T. Kessler, G. Lenz, R.M. Mesters, C. Schliemann | Department of Medicine A, University Hospital, Muenster, Germany
2PDF: 0 -
OC09 | BLEEDING RISK ASSOCIATED WITH FACTOR XI MONOCLONAL ANTIBODIES IN COMBINATION WITH ASPIRIN IN HEALTHY VOLUNTEERS AND ORTHOPEDIC SURGERY PATIENTS: ANALYSIS FROM RECENT PHASE 1 AND PHASE 2 STUDIES A.P. Kithcart1, M.E. Burczynski1, P. Banerjee1, M. Onisko1, Y. Wang1, K. Mohammadi1, D. Li1, S. Li1, J. Ackroyd2, B.A. Olenchock1, D.E. Gutstein1, J. I. Weitz3 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Clinical Research, Fortrea Clinical Research Unit Ltd, Leeds, UK; 3McMaster University, Hamilton, ON, Canada
1PDF: 1 -
OC08 | A SILK-BASED 3D BONE MARROW MODEL FOR CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA C.A. Di Buduo, M. Migliavacca, A. Malara, A. Balduini | Department of Molecular Medicine, University of Pavia, Italy
4PDF: 1 -
OC06 | PRIMARY THROMBOPROPHYLAXIS IN ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA UNDERGOING SYSTEMIC ANTICANCER TREATMENT: A CANCER-CENTER COHORT STUDY ON CLINICAL PRACTICE AND OUTCOMES F. Haque1|2, A. Adekeye1|2, Z. Mohtashim2, K. Page1, M. Goodman1, A. Maraveyas 1|2 | 1Hull University Teaching Hospital NHS Trust, UK; 2Hull York Medical School, UK
6PDF: 1 -
OC05 | TIME TO START OF ANTICOAGULANT THERAPY AND SURVIVAL OUTCOMES IN CANCER PATIENTS WITH PULMONARY EMBOLISM K. Bria, B. Gage, M. Bealsey, K. Sanfilippo | Washington University in St. Louis School of Medicine, St. Louis, MO, USA
1PDF: 0 -
OC04 | DIRECT ORAL ANTICOAGULANTS PROVIDE EFFECTIVE THROMBOPROPHYLAXIS IN NEWLY DIAGNOSED MYELOMA: REAL WORLD FINDINGS FROM THE ATOMM STUDY T. Bull1, Heamstar Collaborators2, W. Wilson3, E. Ganendra4, M. Thomas5, R. Alikhan6, M. Karanth1, M. Camilleri7 | 1West Suffolk Hospital NHS Foundation Trust, UK; 2Haematology Specialty Training Audit and Research HaemSTAR Network, UK; 3University College London Clinical Trial Centre, UK; 4North West Anglia NHS Foundation Trust, UK; 5University College London Hospitals, UK; 6Cardiff and Vale University Health Board, Wales, UK; 7Cambridge University Hospitals NHS Foundation Trust, UK
4PDF: 1 -
OC03 | THROMBOEMBOLIC PREVALENCE IN MULTIPLE MYELOMA BEFORE AND AFTER THE INTRODUCTION OF DIRECT ORAL ANTICOAGULANTS: A LONGITUDINAL COHORT STUDY A. Ramírez1, A. Orozco2, A. Sánchez3, F. Villalpa1, S. Burgos2, G. Cesarman3, G. Rodríguez1, D. Vieyra2, J. Álvarez4, G.M. Flores3, S. González1, D. Martínez2, B. Cabello3, R. Espinoza3, O. Fernández3 | 1Myeloma-clinic Hematology service, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, México City, México; 2Myeloma-clinic Hematology service, Instituto Nacional de Nutrición Salvador Zubirán, México City, México; 3Myeloma-clinic Hematology service, Instituto Nacional de Cancerologçia, México City, Mexico; 4Centro Médico Nacional 20 de Noviembre, México City, Mexico
3PDF: 0 -
OC02 | INCIDENCE AND PREDICTORS OF ARTERIAL THROMBOSIS IN CANCER PATIENTS: RESULTS FROM THE PROSPECTIVE COMPASS-ARTERIAL CANCER ASSOCIATED THROMBOSIS (COMPASS-ARTECAT) STUDY M. Drakopoulou1, I. Diamandoulaki2, P. Baglaridis1, P. Las Casa3, P. Van Dreden4, K. Toutouzas1, G. Gerotziafas4|5 | 1First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, Greece; 2Department of Electrical and Computer Engineering, Aristotle University of Thessaloniki, Thessaloniki, Greece; 3Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP) Paris France; 4Diagnostica Stago, clinical research, Gennevilliers, France; 5Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Ill., USA
7PDF: 1 -
Platelet-driven remodeling of cancer cell glycoproteins fuels inflammation and metastasis
0PDF: 0Extra Tables: 0Extra Figure 1: 0Extra Figure 2: 0
1 - 98 of 98 items
